Publications by authors named "E Lopez-Crapez"
Background: Triplet chemotherapy plus cetuximab showed promising results in phase II trials in unsystematically selected RAS population. We evaluated FOLFIRINOX+cetuximab efficacy as first-line treatment in extended RAS wild-type metastatic colorectal cancer (mCRC) patients.
Methods: We retrospectively analyzed patients treated with FOLFIRINOX+cetuximab, using data from clinical trials and real-life practice.
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological cancers in Western countries. High-Grade Serous Ovarian Carcinoma (HGSOC) accounts for 60-70% of EOC and is the most aggressive subtype. Reduced PTPN13 expression levels have been previously correlated with worse prognosis in HGSOC.
View Article and Find Full Text PDFArticle Synopsis
- Triple-negative breast cancers (TNBCs) generally have poor outcomes, but the role of tumor-associated macrophages (TAMs) in their progression hasn't been fully understood, leading to mixed findings.
- A study of 285 non-metastatic TNBC patients found that certain macrophage markers (like CD68, IRF8, and CD163) were linked with worse tumor characteristics, while CD206 was tied to smaller tumors and better survival rates.
- The results indicate that CD206+ TAMs may signify a subgroup of TNBC patients who could respond more favorably to immunotherapy, suggesting potential new treatment strategies.
Besides the standard parameters used for colorectal cancer (CRC) management, new features are needed in clinical practice to improve progression-free and overall survival. In some cancers, the microenvironment mechanical properties can contribute to cancer progression and metastasis formation, or constitute a physical barrier for drug penetration or immune cell infiltration. These mechanical properties remain poorly known for colon tissues.
View Article and Find Full Text PDFBackground: Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be converted to resectable with chemotherapy plus a targeted therapy. We assessed which of chemotherapy doublet (2-CTx) or triplet (3-CTx), combined with targeted therapy by RAS status, would be better in this setting.
View Article and Find Full Text PDF